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esses: davariel@zahav.nSummary Objective: Corticosteroids play a key role in immunosuppression after
transplantation. However, because chronic steroid treatment may cause significant
morbidity and mortality, steroid-free immunosuppression remains a desirable goal.
To the best of our knowledge, there are no reports on successful steroid withdrawal
(SW) in lung transplant recipients.
Methods: The study group included 35 patients who underwent heart–lung,
double-lung or single-lung transplantation. Criteria for initiation of SW were stable
pulmonary function tests and absence of clinical or bronchoscopic evidence of acute
or chronic rejection in the last 6 months. Pulmonary function, blood pressure and
metabolic parameters were compared between the patients who underwent SW and
those who did not.
Results: Eight patients (23%) underwent SW. Median follow-up was 19 months
(range 11–23 months). Compared to the non-withdrawal group, the withdrawal
group was older (60767vs. 52713 years, P ¼ 0:01; r ¼ 0:49), had higher rates of
emphysema (88% vs. 18%, P ¼ 0:01) and use of a cyclosporine-based regimen (62% vs.
26%, P ¼ 0:0001), and had longer time from transplantation to the withdrawal
attempt (70713 vs. 29726 months, P ¼ 0:0002). The SW group showed no adverse
effects in graft function and no deterioration on pulmonary function tests. SW had a
beneficial metabolic effect, with a decrease in mean cholesterol level from 229745
to 194725mg/dl (P ¼ 0:02) and no significant change in weight, systolic blood
pressure or glucose level. In the non-withdrawal group, mean cholesterol levels
increased from 175734 to 209757mg/dl (P ¼ 0:0005), weight increased from
72715 to 80714 kg (P ¼ 0:0001), and systolic blood pressure increased from
125715 to 139716mmHg (P ¼ 0:001); glucose levels did not change. There was aPublished by Elsevier Ltd.
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Steroid withdrawal in lung transplant 597significant correlation between total cholesterol level and weight in both groups
(P ¼ 0:0006; r ¼ 0:56 and P ¼ 0:01; r ¼ 0:46; respectively).
Conclusions: Late SW is safe in stable patients after lung transplantation. There
was no evidence of rejection or a deterioration in pulmonary function. Lipid profile
improvement and blood pressure stabilization accompanied the termination of
steroid therapy.
& 2004 Published by Elsevier Ltd.Introduction
Corticosteroids have been available for more than
50 years and have played a key role in the evolution
of successful organ transplantation. Most transplant
physicians and surgeons agree, however, that side
effects associated with these agents are responsi-
ble for a large number of long-term complications,
including increased susceptibility to infections,
dermatological problems, behavioral changes, cat-
aracts and skeletal effects such as osteopenia and
osteoporosis, aseptic necrosis and impaired
growth.1–6 Moreover, steroid therapy may increase
the risk of cardiovascular disease, an important
cause of post-transplant morbidity and mortality.7
The introduction of cyclosporine and tacrolimus
(FK 506) has improved the results of transplanta-
tion and has allowed a reduction in the dosage of
corticosteroids for maintenance therapy.8,9 Never-
theless, patients still develop steroid-related side
effects, mainly diabetes, hypertension, hyperlipi-
demia and obesity.10 Steroid-induced diabetes has
been associated with an increased incidence of
infections and a decrease in patient and graft
survival.6,11 Thus, the institution of a steroid-free
immunosuppressive regimen is highly desirable.
The benefits of eliminating steroids, however, must
be weighed against the risk of promoting acute or
chronic allograft rejection.12,13
In the last few years, several attempts to
withdraw steroids in transplant recipients of solid
organs have been made.14–22 These reports found
late withdrawal to be usually safe in the renal,
liver, heart and pancreatic transplantation.20–22 To
the best of our knowledge, there are no reports on
steroid withdrawal SW following lung transplanta-
tion. We present our experience with SW in
selected stable lung transplant recipients and
compare the metabolic and pulmonary effects with
patients in whom steroids were not withdrawn.Patients and methods
The study sample included 35 patients who under-
went heart–lung (n ¼ 4), double-lung (n ¼ 4) orsingle-lung (n ¼ 27) transplantation between May
1994 and December 2002. Immunosuppression
before SW consisted of a combination of predni-
sone, azathioprine and cyclosporine. Patients
operated on after November 1998 were treated
with prednisone, mycophenolate mofetil and
tacrolimus. All the transplant recipients received
prophylaxis with itraconazole, trimethoprim-sulfa-
methoxazole, ganciclovir and oral nystatin. Sur-
veillance bronchoscopies were done during the SW
period according to clinical need.
Criteria for SW included stable post-transplanta-
tion pulmonary function tests (PFTs) (decline of no
more than 10% in forced expiratory volume in 1 s
(FEV1) or forced expiratory flow at 25–75% (FEF
25–75%)) and no histological evidence of rejection
on surveillance bronchoscopy in the previous 6
months. The SW period was adjusted to the clinical
status of the patients (median 3 months, range 2–5
months). Every step included a decrease of 5mg
prednisone from the last dosage. Blood pressure
and metabolic parameters (glucose and lipid
profile) before and after follow-up were compared
between the patients who underwent withdrawal
and those who did not.Statistical analysis
Continuous variables are shown as means7stan-
dard deviations. Paired t-test was used to analyze
statistically significant differences in mean contin-
uous parameters before and after steroid with-
drawal, and chi-square test in Fisher’s exact test
was used to analyze statistically significant rela-
tionships between categorical variables. A P value
less than or equal to 0.05 was considered statisti-
cally significant.Results
Baseline characteristics
Baseline characteristics of the SW and non-steroid-
withdrawal (NSW) groups are shown in Table 1. SW
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Table 1 Baseline characteristics of the SW and NSW groups.
Characteristicsa Between-group analysis
SW NSW P r
Malea 7 (88) 22 (81) 0.70 0.07
Age (mean7SD) 6076 52713 0.01 0.49
Tacrolimus-based regimen 3 (38) 20 (74) 0.001 0.51
Lung disease
Pulmonary fibrosis 1 (13) 20 (74) 0.01 —
Emphysema 7 (88) 5 (18) 0.01 —
Primary pulmonary hypertension 0 (0) 1 (4) 0.24 —
a-1-antitrypsin 1 (13) 0 (0) 0.79 —
Cystic fibrosis 0 (0) 1 (4) 0.23 —
Duration since transplant (mean7SD) 70713 29726 0.0002 0.60
aValues are N (%) unless otherwise indicated.
Table 2 Pulmonary function, metabolic effects and mean systolic blood pressure in the SW and NSW groups
before and after follow-up (median 19 months).
Parameters SW NSW Between-group analysis
Before After P-value Before After P-value P-value r
FEV1 (%)
a 67721 67717 NS 62721 54718 NS NS NS
FEF 25–75%a 48736 55735 NS 52731 41729 NS NS NS
Total cholesterol (mg/dl)a 229745 194725 0.02 175734 209757 0.005 0.0006 0.56
Glucose (mg/dl)a 96719 91715 NS 105738 99721 NS NS NS
Weight (kg)a 66713 65713 NS 72715 80714 0.0001 0.01 0.46
Systolic BP (mmHg)a 1417112 143711 NS 125715 139716 0.001 NS NS
FEV1=forced expiratory volume in 1 s; FEF 25–75%=forced expiratory flow at 2575%; BP=blood pressure.
aAll values given as mean7SD.
D. Shitrit et al.598was completed successfully in eight patients (23%)
and not done in 27. The NSW group included 22
males (81%); mean age was 52713 years compared
to 6076 years in the SW group (P ¼ 0:01; r ¼ 0:49).
Tacrolimus-based immunosuppression was adminis-
tered to 20 patients (74%) in the NSW group and
three (38%) in the SW group (P ¼ 0:001), r ¼ 0:51).
In the NSW group, 20 patients (74%) underwent
transplantation for pulmonary fibrosis, five for
emphysema, one for primary pulmonary hyperten-
sion and one for cystic fibrosis. In the SW group,
only one patient had fibrosis, six had emphysema
and one had a-1-antitrypsin (P ¼ 0:01). Mean time
(7 SD) from transplantation to the SW attempt was
29726 months in the NSW group and 70713
months in the SW group (P ¼ 0:002; r ¼ 0:60).
Reasons for nonperformance of SW were unstable
PFT’s in 21 patients and bronchiolitis obliterans
with poor lung function in six patients.Pulmonary function (Table 2)
There was no change in either FEV1 or FEF 25–75%
after SW. The mean FEV1 measured 67721% before
withdrawal and 67717% after (P ¼ 0:50); corre-
sponding values for FEF 25–75% were 48736% and
55735% (P ¼ 0:13). Pulmonary function in the NSW
group included FEV1: 62721% before follow-up and
54718% after; FEF 25–75%: 52731% before and
41729% after (P ¼ NS).Metabolic effects and systolic blood pressure
Lipid profile (cholesterol), mean weight, systolic
blood pressure and glucose levels in the two groups
are shown in Table 2. None of the patients in either
group started treatment with statin. A significant
improvement in lipid profile was noted after steroid
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Steroid withdrawal in lung transplant 599withdrawal, with cholesterol levels dropping from
229745 to 194725mg/dl (P ¼ 0:02). There were
no statistically significant changes in the SW group
in body weight (66713 vs. 65712.6 kg) or systolic
blood pressure (141712 vs. 143711mmHg). In
contrast, the NSW group was characterized by a
significant increase in cholesterol levels (from
175734 to 209757mg/dl, P ¼ 0:0005), weight
(72715 to 80714 kg, P ¼ 0:0001) and systolic
blood pressure (125715 to 139716mmHg,
P ¼ 0:001). No statistically significant changes were
noted in glucose level.
Comparison of the changes between the groups
(Table 2) yielded significant differences for total
cholesterol and mean weight gain (P ¼ 0:0006; r ¼
0:56 and P ¼ 0:01; r ¼ 0:46; respectively).Discussion
Our review of the literature revealed that SW has
been completed successfully in several types of
organ transplantation.
Graft function
Opelz23 reported that in renal transplant recipients
initially prescribed triple therapy, the 5-year graft
survival rate was significantly higher in patients
switched to steroid-free immunosuppression (87%)
than in patients who remained on triple therapy
(76%) or in patients maintained on cyclosporine and
corticosteroids (79%). SW did not lead to a
deterioration in graft function in most cases.
Accordingly, Matl et al.14 assessed the risk of
rejection in 46 stable renal transplant recipients
who underwent steroid withdrawal and 42 who
continued triple-drug therapy. Graft rejection
occurred in three patients in each group and
leukopenia in one patient in the withdrawal group.
There was no significant between-group difference
in creatinine level at the 1-year follow-up.
However, the risk of rejection rises significantly if
SW is initiated in the early post-transplant period.
Ahsan et al.,20 in a study of renal transplant
recipients who underwent steroid withdrawal 3
months after surgery, found that the rate of
rejection and treatment failure (death, graft loss
or refractory rejection) increased from 9.8% to
30.8%. In contrast, at 1 year after transplantation,
there was no difference in patient or graft survival
between those who underwent SW and those who
did not. Ratcliffe et al.24 noted that although there
were no cases of acute rejection after SW in stable
renal transplant recipients, most of the patientsshowed an insidious increase in creatinine levels,
which may or may not have been transient.
Everson et al.16 reviewed 16 reports on a total of
749 adults after liver transplantation. They found
that early SW was not associated with future
rejection or adverse effects on patient and graft
survival. The same results were observed when
withdrawal was done 1 year after transplanta-
tion.21 Different rejection rates were reported in
two studies of heart transplant recipients,17,18
although both found similar or improved survival
and graft function after SW. In our study, no
rejection was noted in stable lung recipients who
underwent SW.Metabolic effects
SW was associated with beneficial metabolic
effects, including decreased cholesterol level, in
three relevant studies,14,20,24 and with lower blood
pressure in two of them20,24 (Table 3). In the study
of Everson et al.16 in liver transplant recipients,
early SW (less than 3 months) was associated with a
reduced rate and better control of hypertension,
reduced total cholesterol levels and improved
control of diabetes. Gomez et al.21 found the same
trend in stable liver transplant recipients who
underwent SW more than 1 year after transplanta-
tion. Olivari et al.18 assessed the impact of SW 6
months after heart transplantation. The degree of
weight gain, lipid abnormalities and incidence of
hypertension was not modified by tapering pre-
dnisone, whereas the incidence of cataract and
compression fracture was significantly reduced.
This improvement in metabolic parameters after
SW can contribute to longer patient survival.
Although our study was small and uncontrolled,
to the best of our knowledge, it is the first to be
conducted in stable lung transplant recipients after
SW. Owing to the high incidence of rejection and
infections in lung transplant recipients compared to
recipients of other solid organs, we applied rigid
inclusion criteria. The significant difference in
mean duration from transplantation to the SW
attempt between the two groups (70713 vs.
29726 months, P ¼ 0:0002) reflects the time
needed for the patients to stabilize. Most of the
patients who underwent SW had emphysema,
whereas most of those who did not had fibrosis.
Although most of the emphysematous patients in
our study were older and were still being treated
with a cyclosporine-based regimen, SW did not
affect graft function, and FEV1 and FEF 25–75%
remained stable during follow-up. SW also led to
improvement in total cholesterol levels (P ¼ 0:02)
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D. Shitrit et al.600and stabilization of systolic blood pressure. The
markedly high pre-follow-up of cholesterol in the
NSW group compared with the SW group (229 vs.
175mg/dl) may be attributed to the long-term
effect of steroids in these patients. Glucose level
remained stable throughout follow-up in both
groups, whereas weight, systolic blood pressure
and cholesterol level increased significantly
(P ¼ 0:0001; 0.001 and 0.0005, respectively) in
the NSW group.
It should be mentioned, however, that data from
renal transplant recipients have indicated that
adverse effects of SW first appear only after 5
years.23
We conclude that late withdrawal of steroids
after lung transplantation is safe in stable patients.
No increase in the number of rejections and no
deterioration in pulmonary function was noted.
There was a clear trend toward a reduction in
cholesterol levels after 19 months. A longer-term
randomized controlled study is needed to confirm
our results. Further improvement is expected on
longer follow-up in glucose metabolism and weight
control and in other parameters such as bone
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